LAS VEGAS, March 15, 2010 (GLOBE NEWSWIRE) -- It has been a very eventful year for SenoRx Inc. (Nasdaq:SENO) as the company focused on the intersection of women's health and oncology has seen its stock price rise precipitously and the grey clouds of a patent lawsuit subside. For SenoRx, it is indeed a new day.
It is interesting to consider what SenoRx might have accomplished without the distraction of litigation taxing the equity, and thus been able to fully focus on a business plan known for its robust product pipeline and strong distribution channels.
In 2009 alone, SenoRx was able to roll-out numerous innovative product developments within the breast cancer arena, offering health care providers both diagnostic and therapeutic technologies to better detect and treat breast cancer. Each product offering simultaneously increased SenoRx's revenue opportunities while enhancing its reputation in the health care community.
A couple of examples were the next generation of Contura, known as "Shape Select", a multi-lumen balloon that allows greater conformity to lumpectomy cavities. Another is "StarchMark", a unique marker to help control bleeding as well as improve marker centration for users.
Currently, SenoRx has plans for this year to develop a second-generation EnCor system, a new targeted model of SenoSonix for use in a radiology department and a next-generation radiation therapy product. Market opportunities for a new RFID tag and accompanying handheld reader for lesion localization are also being explored. Singularly and collectively these are major product launch events for SenoRx as they enable them to continue their rapid growth in breast care and further cement their footprint in this key market segment at the forefront of the medical device technology market.
Similarly, it is intriguing to ponder how Wall Street views the diminished worry related to the infringement lawsuit. A traditional axiom holds that among the greatest detractions to a stock price is uncertainty. The former prospect of the uncertain outcome of a patent lawsuit with one of SenoRx's top competitors certainly qualifies.
But again, with the favorable December 2009 decision, SenoRx should now be able to fully turn its energies and resources to what it has proven all along, what it is indeed now known for, the betterment of women's breast cancer treatment.
Statements herein may contain forward-looking statements and are subject to significant risks and uncertainties affecting results. Small Cap Sentinel is property of Integrity Media Inc. (IMI). IMI provides no assurance as to the subject company's plans or ability to effect proposed actions and cannot project capabilities, intent, resources, or experience. The subject companies haven't always approved the statements made in this report. This report is neither a solicitation to buy nor offer to sell securities and is for information purposes only and shouldn't be used as basis for investment decisions. IMI isn't an investment advisor, analyst or licensed broker dealer and this report isn't investment advice. IMI has been paid thirty-thousand dollars by SenoRx for this report and other services to be performed over the remainder of the calendar year. Paid reports constitute a conflict of interest as to IMI's ability to remain objective in communication regarding subject companies.